Takeda Pharmaceutical agreed to buy London-listed Shire for 45.3 billion pounds ($62 billion) on Tuesday, the biggest yet in a wave of deals sweeping the drugs industry.
The Emmes Corporation today announced that scientists and health professionals from the company, LDS Hospital in Salt Lake City, Utah, Lovelace Biomedical Environmental Research Institute in Albuquerque, New Mexico, and the U.S. Army Medical and Materiel Development Activity at Fort Detrick, Maryland, have completed a multi-year clinical trial testing hyperbaric oxygen as an intervention for U.S. military service members who have suffered mild traumatic brain injuries with persistent symptoms.
The first-quarter numbers for Emergent BioSolutions (NYSE:EBS) didn’t look too great. In fact, they were arguably ugly.
Rockville-based BeneVir Biopharm Inc., a biotech specializing in immunotherapy treatments for cancer, has reached a deal to sell to pharmaceutical goliath Janssen Biotech Inc., a Johnson & Johnson company, in a deal worth up to $1.04 billion.
Think of The Collective as a 15K SF clubhouse for big kids. Grownups are welcome, but leave your electronic devices in your pockets, please. This is about face-to-face fun.
In this second part of two episodes, Rich sits down with leaders from different parts of the BHCR to talk about what they are working on, and their thoughts on the event. His guests are Todd Haim, SBIR Director, NCI SBIR Development Center at NIH, and Matthew McMahon, Director, Office of Translational Alliances and Coordination at the National Heart, Lung, and Blood Institute at NIH
Listen now on iTunes , Google Play , and TuneIn.
In this first part of two episodes, Rich sits down with leaders from different parts of the BHCR to talk about what they are working on, and their thoughts on the event. His guests are Jim Jackson, SVP, CSO at Emergent BioSolutions and Jim Hughes, Vice President at University of Maryland, Baltimore.
Listen now on iTunes , Google Play , and TuneIn.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,129,744 patient records were breached between January and March 2018, according to new data released today in the Protenus Breach Barometer. Published by Protenus, an artificial intelligence platform used by top health systems to analyze every access to patient data inside the electronic health record (EHR), the Breach Barometer is the industry’s definitive source for health data breach reporting.
Landos Biopharma, Inc., an emerging biopharmaceutical company focused on developing improved treatments for autoimmune diseases, announced the publication of findings on the mechanisms of action for its top lead candidate, BT-11, in Inflammatory Bowel Diseases, the Official Journal of the Crohn’s & Colitis Foundation. The study concludes that through the activation of the Lanthionine Synthetase C-Like 2 (LANCL2) pathway, BT-11 induces changes in the interface of inflammation and metabolism within immune cells in the gut that are critical to provide lasting therapeutic efficacy against inflammatory bowel disease (IBD). These changes in metabolism enhance regulatory CD4+ T helper cell responses and promote lasting therapeutic actions locally within the gut. The mechanistic findings demonstrate the translatability of the therapeutic efficacy of BT-11 to the clinic.